February 13, 2008Expert Opinion on Therapeutic Targets

Therapeutic targets in hypertension: is there a place for antagonists of the most potent vasoconstrictors?

View Full Paper

Ask AI

Bookmark

Population

Patients with hypertension and cardiovascular/renal diseases

Design

Review

Authors

FGFernanda RC Giachini GCGláucia E. CalleraUniversity of Ottawa FCFernando S. CarneiroUnited States Nuclear Regulatory Commission

Discussion

Member takes

Implication

ET-1 and U-II antagonists merit prospective trials in cardiovascular and renal disease; leaves open clinical translation pending higher-level evidence.

Structured PICO

Population

Patients with hypertension and cardiovascular/renal diseases

Intervention

Endothelin-1 (ET-1) and urotensin II (U-II) receptor antagonists

Endothelin-1 and urotensin II are potent vasoconstrictors with pro-inflammatory properties that play a role in the pathogenesis of hypertension, highlighting their antagonists as potential therapeutic targets.

Cite This Study

Giachini et al. (2008) studied this question.

synapsesocial.com/papers/6a100751b6f5ee0401603537 https://doi.org/10.1517/14728222.12.3.327

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Implication

ET-1 and U-II antagonists merit prospective trials in cardiovascular and renal disease; leaves open clinical translation pending higher-level evidence.

Therapeutic targets in hypertension: is there a place for antagonists of the most potent vasoconstrictors?

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Topics

Therapeutic targets in hypertension: is there a place for antagonists of the most potent vasoconstrictors?

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider